Evidence map›Paper›PMID 28958809›Full record

ArticleVaccine2018

Impact of rotavirus vaccine on all-cause diarrhea and rotavirus hospitalizations in Madagascar.

V L Rahajamanana, J L Raboba, A Rakotozanany, N J Razafindraibe, E J P R Andriatahirintsoa, A C Razafindrakoto, S A Mioramalala, C Razaiarimanga, G G Weldegebriel, E Burnett and 4 more

Abstract read
In one paragraph

Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. A phase I trial of WRSS1, aHuman vaccines & immunotherapeutics · 2019
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Impact of 10-Valent Pneumococcal Conjugate Vaccine on Bacterial Meningitis in Madagascar.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

V L RahajamananaDepartment of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar. Electronic address: v_lalaina@yahoo.fr.
J L RabobaDepartment of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar.
A RakotozananyDepartment of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar.
N J RazafindraibeTeaching Hospital, Centre Hospitalier Universitaire Andohatapenaka, Antananarivo, Madagascar.
E J P R AndriatahirintsoaTeaching Hospital, Centre Hospitalier Universitaire Anosiala, Antananarivo, Madagascar.
A C RazafindrakotoDepartment of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar.
S A MioramalalaNational Malaria Country Program, Public Health Ministry, Antananarivo, Madagascar.
C RazaiarimangaWHO Country, Madagascar.
G G WeldegebrielWHO Inter-Country Support Team: East and Southern Africa (WHO IST/ESA), Harare, Zimbabwe.
E BurnettFoundation for the Centers for Disease Control and Prevention, Division of Viral Diseases, Atlanta, USA.
J M MwendaWorld Health Organization (WHO) Regional Office for Africa (WHO/AFRO), Brazzaville, Congo.
M SeheriRegional Rotavirus Reference Laboratory, SAMRC/Diarrheal Pathogens Research Unit, Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
M J MphahleleRegional Rotavirus Reference Laboratory, SAMRC/Diarrheal Pathogens Research Unit, Department of Virology, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
A L RobinsonDepartment of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar.
Sefako Makgatho Health Sciences University · ZASouth African Medical Research Council · ZAThe Centers · USUniversity of Antananarivo · MGWorld Health Organization Regional Office for Africa · CGWorld Health Organization - Zimbabwe · ZW

Funding

Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

backgroundRotavirus vaccine was introduced into the Extended Program on Immunization in Madagascar in May 2014. We analyzed trends in prevalence of all cause diarrhea and rotavirus hospitalization in children <5years of age before and after vaccine introduction and assessed trend of circulating rotavirus genotypes at Centre Hospitalier Universitaire Mère Enfant Tsaralalàna (CHU MET).

methodsFrom January 2010 to December 2016, we reviewed the admission logbook to observe the rate of hospitalization caused by gastroenteritis among 19619 children <5years of age admitted at the hospital. In June 2013-December 2016, active rotavirus surveillance was also conducted at CHUMET with support from WHO. Rotavirus antigen was detected by EIA from stool specimen of children who are eligible for rotavirus gastroenteritis surveillance at sentinel site laboratory and rotavirus positive specimens were further genotyped at Regional Reference Laboratory by RT-PCR.

resultsDiarrhea hospitalizations decreased after rotavirus vaccine introduction. The median proportion of annual hospitalizations due to diarrhea was 26% (range: 31-22%) before vaccine introduction; the proportion was 25% the year of vaccine introduction, 17% in 2015 and 16% in 2016. Rotavirus positivity paralleled patterns observed in diarrhea. Before vaccine introduction, 56% of stool specimens tested positive for rotavirus; the percent positive was 13% in 2015, 12% in 2016. Diverse genotypes were detected in the pre-vaccine period; the most common were G3P[8] (n=53; 66%), G2P[4] (n=12; 15%), and G1P[8] (n=11; 14%). 6 distinct genotypes were found in 2015; the most common genotype was G2P[4] (n=10; 67%), the remaining, 5, G12[P8], G3[P8], G1G3[P4], G3G12[P4][P8] and G1G3[NT] had one positive specimen each.

conclusionsFollowing rotavirus vaccine introduction all-cause diarrhea and rotavirus-specific hospitalizations declined dramatically. The most common genotypes detected in the pre-vaccine period were G3P[8] and G2P[4] in 2015, the post vaccine period.

Indexed as

Immunization ProgramsAntigens, ViralChild, PreschoolDiarrheaFecesGastroenteritisGenotypeHospitalizationHospital RecordsHumansInfantMadagascarPrevalenceRotavirusRotavirus InfectionsRotavirus VaccinesAntigens, ViralRIX4414 vaccineRotavirus VaccinesVaccines, AttenuatedGenotypeRotavirusRotavirus vaccineSurveillance

Identifiers

PMID28958809
PMCPMC5867203
OpenAlexW2757311760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.